Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study

NCT02549092 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02549092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02549092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
October 26, 2015
Completion date
November 18, 2022
Enrollment
89 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

advanced parkinson's disease